摘要
目的探讨在中晚期食管癌治疗中采取卡培他滨联合同步放化疗治疗的价值。方法选取2019年1月—2022年12月广西贺州市人民医院收治的82例中晚期食管癌患者为研究对象,用随机数表法分成研究组(41例)和比较组(41例),比较组实施同步放化疗方案,研究组在比较组基础上加用卡培他滨,比较两组临床疗效、免疫功能、炎性因子。结果研究组临床总有效率高于比较组(82.93%vs 60.98%),差异有统计学意义(χ^(2)=4.895,P<0.05);治疗前,两组患者免疫功能比较,差异无统计学意义(P>0.05);治疗后,研究组免疫功能优于比较组,差异有统计学意义(P<0.05);治疗前,两组患者炎性因子对比,差异无统计学意义(P>0.05);治疗后,研究组炎性因子水平低于比较组,差异有统计学意义(P<0.05)。结论在中晚期食管癌治疗中采取卡培他滨联合同步放化疗治疗方案,可以促进临床疗效提高,改善免疫功能,缓解炎症反应。
Objective To explore the value of capecitabine combined with synchronized chemoradiotherapy in the treatment of middle and advanced esophageal cancer.Methods A total of 82 patients with middle and advanced esophageal cancer admitted to Guangxi Hezhou People's Hospital from January 2019 to December 2022 were selected as the study subjects.They were divided into study group(41 cases)and comparison group(41 cases)by random number table method.The comparison group was given concurrent chemoradiotherapy,and capecitabine was added to the study group on the basis of the comparison group.The clinical efficacy,immune function and inflammatory factors were compared between the two groups.Results The total clinical effective rate of the study group was higher than that of the comparison group(82.93%vs 60.98%),and the difference was statistically significant(χ^(2)=4.895,P<0.05).Before treatment,there was no significant difference in immune function between the two groups(P>0.05).After treatment,the immune function of the study group was better than that of the comparison group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in inflammatory factors between the two groups(P>0.05).After treatment,the level of inflammatory factors in the study group was lower than that in the comparison group,and the difference was statistically significant(P<0.05).Conclusion Adopting capecitabine combined with synchronized chemoradiotherapy treatment regimen in the treatment of middle and advanced esophageal cancer can promote the improvement of clinical efficacy,improve the immune function and alleviate the inflammatory response.
作者
徐庆萍
马荣贵
粟晓娟
XU Qingping;MA Ronggui;SU Xiaojuan(Department of Medical Oncology,Guangxi Hezhou People's Hospital,Hezhou,Guangxi Zhuang Autonomous Region,542899 China)
出处
《系统医学》
2024年第7期110-112,116,共4页
Systems Medicine
关键词
中晚期食管癌
卡培他滨
同步放化疗
Middle and advanced esophageal cancer
Capecitabine
Synchronized chemoradiotherapy
